From the Alzheimer's Association:
The Alzheimer drug latrepirdine (Dimebon) did not meet either of its primary research targets in a late-stage clinical study, faring no better than a placebo at treating the disease, according to Pfizer Inc., the drug's manufacturer. The Alzheimer’s Association is disappointed to learn of the negative Phase III clinical trial results, but we remain optimistic about the future prospects for better Alzheimer treatments and prevention strategies.
Pfizer is going to continue to test the drug, hoping it might still have some theraputic value, perhaps in concert with other, existing AD treatments. Although my dad is beyond the need for treatment, it saddens me that this drug won't save someone else from our family's pain.
